Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression

被引:20
作者
Ruan, Shu-Qin
Wang, Shan-Wei
Wang, Zhan-Huai
Zhang, Su-Zhan [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
G protein-coupled receptor 30; heregulin; proliferation; migration; invasion; breast cancer; PROTEIN-COUPLED RECEPTOR; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; SIGNALING PATHWAYS; ENDOCRINE RESISTANCE; TYROSINE KINASES; GENE-EXPRESSION; EGF RECEPTOR; HEREGULIN;
D O I
10.3892/mmr.2012.874
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cooperation and communication between different cell signaling transduction pathways are considered critical in the development of various types of cancer as well as drug resistance. There is evidence of crosstalk between the G protein-coupled receptor 30 (GPR30), the newly discovered estrogen receptor (ER), and the ErbB family. Heregulin (HRG)-beta 1, the ligand for ErbB3 and ErbB4, upregulates GPR30 expression in MCF-7, T-47D and BT-474 breast cancer cell lines that express ER alpha. In the present study, recombinant human HRG-beta 1 was used to investigate the upregulation of GPR30 expression by HRGs in MCF-7 breast cancer cells which were ER alpha-positive. In MCF-7 cells, the ErbB2 inhibitor, AG825, the MAPK inhibitor, PD98059, and the MEK1/2 inhibitor, U0126, blocked the HRG-beta 1-induced GPR30 expression. 17-beta-estradiol (E2) boosted the HRG-beta 1-induced proliferation, migration and invasion of MCF-7 cells. Similar to E2, the specific GPR30 agonist, G-1, promoted HRG-beta 1-induced migration and invasion, but inhibited growth. Using the specific GPR30 antagonist, G-15, or the small interfering RNA for GPR30, the functions of GPR30 after treatment with HRG-beta 1 were further investegated. The results from our study indicate that the interruption between GPR30 signaling and the ErbB family system may serve as a promising therapeutic strategy for breast cancer.
引用
收藏
页码:131 / 138
页数:8
相关论文
共 74 条
  • [1] G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells
    Ahola, TM
    Manninen, T
    Alkio, N
    Ylikomi, T
    [J]. ENDOCRINOLOGY, 2002, 143 (09) : 3376 - 3384
  • [2] Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells
    Ahola, TM
    Purmonen, S
    Pennanen, P
    Zhuang, YH
    Tuohimaa, P
    Ylikomi, T
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (10): : 2485 - 2490
  • [3] Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review)
    Al Saleh, Sanaa
    Sharaf, Leyla H.
    Luqmani, Yunus A.
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (05) : 1197 - 1217
  • [4] Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells
    Albanito, Lidia
    Sisci, Diego
    Aquila, Saveria
    Brunelli, Elvira
    Vivacqua, Adele
    Madeo, Antonio
    Lappano, Rosamaria
    Pandey, Deo Prakash
    Picard, Didier
    Mauro, Loredana
    Ando, Sebastiano
    Maggiolini, Marcello
    [J]. ENDOCRINOLOGY, 2008, 149 (08) : 3799 - 3808
  • [5] Neuregulin-regulated gene expression in mammary carcinoma cells
    Amin, DN
    Tuck, D
    Stern, DF
    [J]. EXPERIMENTAL CELL RESEARCH, 2005, 309 (01) : 12 - 23
  • [6] The G Protein-Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor-Positive Breast Cancer Cells
    Ariazi, Eric A.
    Brailoiu, Eugen
    Yerrum, Smitha
    Shupp, Heather A.
    Slifker, Michael J.
    Cunliffe, Heather E.
    Black, Michael A.
    Donato, Anne L.
    Arterburn, Jeffrey B.
    Oprea, Tudor I.
    Prossnitz, Eric R.
    Dun, Nae J.
    Jordan, V. Craig
    [J]. CANCER RESEARCH, 2010, 70 (03) : 1184 - 1194
  • [7] Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion
    Arora, P.
    Cuevas, B. D.
    Russo, A.
    Johnson, G. L.
    Trejo, J.
    [J]. ONCOGENE, 2008, 27 (32) : 4434 - 4445
  • [8] Atlas E, 2003, MOL CANCER RES, V1, P165
  • [9] Virtual and biomolecular screening converge on a selective agonist for GPR30
    Bologa, CG
    Revankar, CM
    Young, SM
    Edwards, BS
    Arterburn, JB
    Kiselyov, AS
    Parker, MA
    Tkachenko, SE
    Savchuck, NP
    Sklar, LA
    Oprea, TI
    Prossnitz, ER
    [J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (04) : 207 - 212
  • [10] Role of heregulin in human cancer
    Breuleux, M.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (18) : 2358 - 2377